Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 688-690, 1997;
This Article
Right arrow Full Text
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brendler, J.
Right arrow Articles by Liu, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brendler, J.
Right arrow Articles by Liu, R. H.
Related Collections
Right arrow Clinical Immunology
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1997;43:688-690.)
© 1997 American Association for Clinical Chemistry, Inc.

Technical Briefs

Initial Test Cutoff Selection Based on Regression Analysis of Initial Test Apparent Analyte Result vs GC/MS Test Analyte Result—Evaluation of Two Radioimmunoassay Kits' Test Data

Jeffery Brendler and Ray H. Liua

Doctoral Training Program in Forensic Sci., Univ. of Alabama at Birmingham, Birmingham, AL 35294-2060
a author for correspondence: fax 205-934-2067, e-mail rliu@sbs.sbs.uab.edu

Current workplace drug-testing programs require reporting positive results only if the gas chromatography/mass spectrometry (GC/MS) results are at or above a cutoff concentration and the mandated initial immunoassay results are also at or above an identical or higher cutoff value. Because immunoassays are generally also responsive to compounds that are structurally related to the analyte, whereas GC/MS analysis is specific for individual compounds, the cutoff adopted for the immunoassay is generally set higher than that adopted for the GC/MS test. The corresponding immunoassay cutoff adopted for the immunoassay may be correlated to that adopted for the GC/MS test if: (a) the drug of abuse is a mixture of structurally related compounds or (b) multiple structurally related metabolites are produced as a result of drug exposure.

We have previously demonstrated that the apparent11-nor-{Delta}9-tetrahydrocannabinol-9-carboxylic acid (9-THC-COOH) concentrations (derived from immunoassays) that statistically correspond to a specific 9-THC-COOH concentration (determined by GC/MS) varied with the immunoassay methodologies used [1] and with the reagent manufacturing dates [2]. In the current study, we evaluate empirical data derived from two RIA kits based on the same technology and available at the same time period, but supplied by two different manufacturers.

Analytical . . . [Full Text of this Article]


Acknowledgments


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.